NEW YORK (GenomeWeb News) – Satoris will collaborate with RayBiotech to develop array-based test kits for Alzheimer's disease, the firms said today.
Satoris, a Redwood City, Calif.-based molecular diagnostics company that has developed a panel of 18 biomarkers that predicted the presence of Alzheimer's disease in test sample sets with up to 90 percent accuracy, will collaborate with RayBiotech, a developer and supplier of multiplex protein detection arrays and array-based test kits.
Under the collaboration, the 18 biomarkers will be applied to the RayBiotech Quantibody array platform. After the array-based test is validated for performance, it will be commercialized later this year as a research-use-only test. Norcross, Ga.-based RayBiotech will market the test, and Satoris will use the array along with proprietary bioinformatic analysis tools to offer a testing service.
"We expect this blood test will be well received as a valuable tool in Alzheimer's research and, potentially, as a diagnostic test as well," said Ray Huang, RayBiotech's president, in a statement. "Using antibody-based approaches, more biomarkers can be identified, validated, and put into clinical application faster and cheaper than with traditional methods based on mass spectrometry."